CHEK2 I157T associates with familial and sporadic colorectal cancer

被引:67
|
作者
Kilpivaara, O.
Alhopuro, P.
Vahteristo, P.
Aaltonen, L. A.
Nevanlinna, H.
机构
[1] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland
[2] Univ Helsinki, Dept Med Genet, Helsinki, Finland
关键词
D O I
10.1136/jmg.2005.038331
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Recently, a functionally defective CHEK2 variant I157T has been proposed to associate with an increased risk of several types of cancer. We investigated the CHEK2 I157T variant for colorectal cancer (CRC) predisposition in a large population based study including a significant number of familial CRC cases. Methods: We screened the CHEK2 I157T variant in a population based series of 1042 Finnish CRC patients using restriction fragment length polymorphism. Mutation status was studied for correlation with clinical characteristics and family history of CRC and other cancers. Results: The frequency of CHEK2I157T was significantly higher in CRC patients (7.8%, 76/972) than in healthy population controls (5.3%, 100/1885) (OR = 1.5, 95% CI 1.1 to 2.1, p = 0.008). The significant association of CHEK2 I157T with CRC was observed among patients with ( 10.4%, 14/135) and without (7.4%, 62/837) a family history of CRC (OR = 2.1, 95% CI 1.1 to 3.7, p = 0.01; OR= 1.4, 95% CI 1.0 to 2.0, p = 0.03; respectively). A trend towards higher variant frequency was also noted among patients with multiple primary tumours and a family history of any cancer. Conclusions: CHEK2 I157T associates with an increased risk of CRC: the association was observed both among familial and sporadic CRC patients. Furthermore, the higher frequency of I157T among patients with multiple primary tumours as well as those with a family history of any cancer supports a role for CHEK2 I157T as a susceptibility allele for multiple cancer types.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] CHEK2 and breast cancer risk
    Coupier, I
    Stoppa-Lyonnet, D
    BULLETIN DU CANCER, 2002, 89 (11) : 921 - 922
  • [32] Synchronous Papillary Thyroid Cancer and Colorectal Cancer in a Young Patient with a CHEK2 Mutation
    Hoskins, Sydney Brooke
    Torgerson, Leslie
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 524 - 531
  • [33] Colorectal cancer risk associated with the CHEK2 1100delC variant
    Katona, Bryson W.
    Yang, Yu-Xiao
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 103 - 105
  • [34] Homozygosity for a CHEK2* 1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype
    van Puijenbroek, M
    van Asperen, CJ
    van Mil, A
    Devilee, P
    van Wezel, T
    Morreau, H
    JOURNAL OF PATHOLOGY, 2005, 206 (02): : 198 - 204
  • [35] Characterization of CHEK2 mutations in prostate cancer
    Wu, Xianglin
    Dong, Xiangyang
    Liu, Wanguo
    Chen, Junjie
    HUMAN MUTATION, 2006, 27 (08) : 742 - 747
  • [36] CHEK2 mutation and hereditary breast cancer
    Narod, Steven A.
    Lynch, Henry T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 6 - 7
  • [37] CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
    Margolin, Sara
    Eiberg, Hans
    Lindblom, Annika
    Bisgaard, Marie Luise
    BMC CANCER, 2007, 7 (1)
  • [38] CHEK2 mutation and hereditary breast cancer
    Bogdanova, Natalia
    Feshchenko, Sergei
    Cybulski, Cezary
    Doerk, Thilo
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : E26 - E26
  • [39] CHEK2 is a multiorgan cancer susceptibility gene
    Cybulski, C
    Górski, B
    Huzarski, T
    Masojc, B
    Mierzejewski, M
    Debniak, T
    Teodorczyk, U
    Byrski, T
    Gronwald, J
    Matyjasik, J
    Zlowocka, E
    Lenner, M
    Grabowska, E
    Nej, K
    Castaneda, J
    Medrek, K
    Szymanska, A
    Szymanska, J
    Kurzawski, G
    Suchy, J
    Oszurek, O
    Witek, A
    Narod, SA
    Lubinski, J
    AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (06) : 1131 - 1135
  • [40] CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
    Sara Margolin
    Hans Eiberg
    Annika Lindblom
    Marie Luise Bisgaard
    BMC Cancer, 7